The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Subclonal evolution and cytogenetic aberrations in myeloma
Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, briefly discusses subclonal evolution in multiple myeloma, and the importance of identifying high-risk cytogenetic markers at diagnosis. Dr Corre explains how gain of chromosome 1q (+1q) is better detected by single-cell analysis and the importance of identifying high-risk markers such as (+1q) or del(17p) at an earlier stage to improve patient prognosis. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
